"Immatics Company Fact Sheet", 20090201, 1 February 2009 (2009-02-01), XP002639217, Retrieved from the Internet: URL:www.immatics.com/index.php?action=down load&id=421> [retrieved on 2011-05-27] (B1)

"Immatics biotechnologies significantly improves XPRESIDENT technology platform", IMMATICS PRESS RELEASE,, [Online] 17 June 2009 (2009-06-17), XP009148860, Retrieved from the Internet: URL:http://www.immatics.com/index.php?page =76&modaction=detail&modid=213& modid2=2009> (B1)

, 17 February 2010 (2010-02-17), XP002639218, Retrieved from the Internet: URL:http://silico.wordpress.com/2010/02/17 /immatics-signs-collaboration-agreement-wi th-cancer-research-uk/ [retrieved on 2011-05-26] (B1)

BIKEYE SANDRA-NADIA NGWABYT ET AL: "ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target", CANCER CELL INTERNATIONAL, BIOMED CENTRAL, LONDON, GB, vol. 10, no. 1, 11 January 2010 (2010-01-11), page 1, XP021067697, ISSN: 1475-2867 (B1)

BioRegio Stern: "immatics biotechnologies stellt nächste Generation der XPRESIDENT-Plattform vor", , 17 June 2009 (2009-06-17), XP002638686, Retrieved from the Internet: URL:http://www.bioregio-stern.de/de/Aktuel les/details_nachrichten.php?OF_ID=4169 [retrieved on 2011-05-25] (B1)

EP-A1- 2 172 211 (B1)

WO-A2-2010/037395 (B1)

WEINSCHENK T ET AL: "Integrated functional genomics approach for the design of patient-individual antitumor vaccines", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER REREARCH, US, vol. 62, no. 20, 15 October 2002 (2002-10-15), pages 5818-5827, XP002266492, ISSN: 0008-5472 (B1)

WO-A1-2009/015841 (B1)

WO-A1-2009/045115 (B1)

WO-A2-02/36614 (B1)

WO-A2-03/100432 (B1)

WO-A2-2007/005635 (B1)

US-A1- 2009 004 213 (B1)